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BACKGROUND
Patients with metastatic triple-negative breast cancer have a poor prognosis. Saci-
tuzumab govitecan is an antibody–drug conjugate composed of an antibody tar-
geting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed 
in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) 
through a proprietary hydrolyzable linker.
METHODS
In this randomized, phase 3 trial, we evaluated sacituzumab govitecan as com-
pared with single-agent chemotherapy of the physician’s choice (eribulin, vinorelbine, 
capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic 
triple-negative breast cancer. The primary end point was progression-free survival 
(as determined by blinded independent central review) among patients without 
brain metastases.
RESULTS
A total of 468 patients without brain metastases were randomly assigned to receive 
sacituzumab govitecan (235 patients) or chemotherapy (233 patients). The median 
age was 54 years; all the patients had previous use of taxanes. The median pro-
gression-free survival was 5.6 months (95% confidence interval [CI], 4.3 to 6.3; 166 
events) with sacituzumab govitecan and 1.7 months (95% CI, 1.5 to 2.6; 150 events) 
with chemotherapy (hazard ratio for disease progression or death, 0.41; 95% CI, 
0.32 to 0.52; P<0.001). The median overall survival was 12.1 months (95% CI, 10.7 
to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with 
chemotherapy (hazard ratio for death, 0.48; 95% CI, 0.38 to 0.59; P<0.001). The 
percentage of patients with an objective response was 35% with sacituzumab go-
vitecan and 5% with chemotherapy. The incidences of key treatment-related ad-
verse events of grade 3 or higher were neutropenia (51% with sacituzumab govite-
can and 33% with chemotherapy), leukopenia (10% and 5%), diarrhea (10% and 
<1%), anemia (8% and 5%), and febrile neutropenia (6% and 2%). There were three 
deaths owing to adverse events in each group; no deaths were considered to be 
related to sacituzumab govitecan treatment.
CONCLUSIONS
Progression-free and overall survival were significantly longer with sacituzumab 
govitecan than with single-agent chemotherapy among patients with metastatic 
triple-negative breast cancer. Myelosuppression and diarrhea were more frequent 
with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov 
number, NCT02574455; EudraCT number, 2017 - 003019 - 21.)
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Patients with metastatic triple-negative breast cancer (defined by a lack of tumor-cell expression of the estrogen re-
ceptor, progesterone receptor, and human epi-
dermal growth factor receptor 2 [HER2]) have 
poor survival outcomes.1,2 Although immuno-
therapy has shown promising first-line clinical 
activity, single-agent chemotherapy remains stan-
dard for previously treated (beyond first-line) 
metastatic triple-negative breast cancer.2-4 How-
ever, chemotherapy is associated with low response 
rates and short progression-free survival.5-9
Sacituzumab govitecan is an antibody–drug 
conjugate composed of an antitrophoblast cell-
surface antigen 2 (Trop-2) IgG1 kappa antibody 
coupled to SN-38, the active metabolite of irino-
tecan and a topoisomerase I inhibitor,10 through 
a proprietary hydrolyzable linker.11,12 Trop-2 is a 
transmembrane calcium signal transducer that 
is highly expressed in multiple tumor types, in-
cluding breast cancer (>90%).13-15 After adminis-
tration, the anti–Trop-2 monoclonal antibody 
binds to Trop-2 expressed on the tumor-cell 
surface and allows for targeted delivery of SN-38 
to tumor cells.12,16 Because free SN-38 is mem-
brane-permeable, it may elicit antitumor effects 
in adjacent tumor cells (bystander effect) before 
internalization of the antibody–drug conjugate 
through hydrolysis of the linker or by intracellular 
SN-38 release after internalization.12,14,17-20
A phase 1–2, single-group, basket trial 
(IMMU-132-01) evaluated sacituzumab govitecan 
monotherapy in metastatic, epithelial cancers.21-23 
In the cohort of 108 patients with metastatic 
triple-negative breast cancer, an objective re-
sponse rate of 33%, a median progression-free 
survival of 5.5 months, and a median overall sur-
vival of 13.0 months was observed with sacituzu-
mab govitecan.23 These results provided the basis 
for accelerated approval by the Food and Drug 
Administration (FDA) in April 2020, with full ap-
proval contingent on the results of the confirma-
tory phase 3 trial.24 Here we provide the primary 
results of the confirmatory phase 3 ASCENT 
trial, a global, open-label, randomized trial evalu-
ating the efficacy and safety of sacituzumab 
govitecan as compared with chemotherapy of the 
physician’s choice (eribulin, vinorelbine, capecita-
bine, or gemcitabine) in patients with relapsed 
or refractory metastatic triple-negative breast can-
cer (Fig. S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org).
Me thods
Patients
We enrolled patients with metastatic triple-nega-
tive breast cancer that was relapsed or refractory 
to two or more previous standard chemotherapy 
regimens (no upper limit) for unresectable, locally 
advanced or metastatic disease; previous therapy 
had to include a taxane (for any indication). Pa-
tients had to have triple-negative breast cancer 
according to standard American Society of Clin-
ical Oncology–College of American Pathologists 
criteria.25 Patients with stable brain metastases 
for at least 4 weeks before treatment were eligi-
ble for the trial but were excluded from the pri-
mary end-point analysis. Additional details are 
provided in the Supplementary Appendix.
Trial Design and Treatment
Patients were randomly assigned in a 1:1 ratio to 
receive sacituzumab govitecan (Trodelvy; Immu-
nomedics, a subsidiary of Gilead Sciences) at a 
dose of 10 mg per kilogram of body weight intra-
venously on days 1 and 8 of each 21-day cycle or 
single-agent chemotherapy as determined before 
randomization: eribulin (1.4 mg per square meter 
of body-surface area [North America] or 1.23 mg 
per square meter [Europe] intravenously on days 
1 and 8 of a 21-day cycle), vinorelbine (25 mg per 
square meter intravenously on day 1 weekly), 
capecitabine (1000 to 1250 mg per square meter 
orally twice daily on days 1 to 14 of a 21-day cy-
cle), or gemcitabine (800 to 1200 mg per square 
meter intravenously on days 1, 8, and 15 of a 
28-day cycle). Patients were stratified at random-
ization according to the number of previous che-
motherapy regimens for advanced disease (2 or 
3 vs. >3), the presence of known brain metastases 
at baseline (yes vs. no), and geographic region 
(North America vs. rest of the world). Treat-
ment was continued until disease progression, 
unacceptable toxic effects, withdrawal from the 
trial, or death, whichever occurred first. No 
crossover to the sacituzumab govitecan group 
was allowed on progression with chemotherapy.
Polymorphisms in the gene encoding uridine 
diphosphate glucuronosyltransferase 1A1 (e.g., 
homozygosity for UGT1A1*28) are associated with 
SN-38 glucuronidation and an increased risk of 
hematologic toxic effects with sacituzumab go-
vitecan.18,23 Therefore, inhibitors and inducers of 
UGT1A1 were used with caution.
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Trial Oversight
The trial was approved by the institutional review 
board or ethics committee at each investiga-
tional site before initiation and was performed 
in accordance with the Declaration of Helsinki, 
International Council for Harmonisation guide-
lines for Good Clinical Practice, the FDA Code 
of Federal Regulations, national and local drug 
and data-protection laws, and other applicable 
regulatory requirements. All the patients provided 
written informed consent before enrollment.
The sponsor team, including former and cur-
rent employees, designed and conducted the trial 
and gathered data in collaboration with the trial 
investigators. Trial oversight was provided by the 
trial steering committee and an independent data 
and safety monitoring committee. The data analy-
sis was performed by Immunomedics, with sta-
tistical service rendered by Covance. The first 
author, with members of the steering committee 
and sponsor, guided the initial manuscript draft 
after an agreement to publish with editorial as-
sistance from professional medical writers fund-
ed by the sponsor. The authors vouch for the 
completeness and accuracy of the data and for 
the fidelity of the trial to the protocol (available 
at NEJM.org). All drafts of the manuscript were 
reviewed and approved by the authors.
Assessments
The primary end point was progression-free sur-
vival (as determined by blinded independent cen-
tral review) among patients without known base-
line brain metastases (measured by computed 
tomography [CT] or magnetic resonance imag-
ing [MRI] according to Response Evaluation 
Criteria in Solid Tumors [RECIST], version 1.126). 
Screening for brain metastasis was not manda-
tory. This prespecified primary end point, ap-
proved by regulatory authorities, allowed for in-
vestigation of the clinical benefit of sacituzumab 
govitecan in patients with metastatic triple-nega-
tive breast cancer without the confounding ef-
fects of brain metastases, a poor prognostic fac-
tor. Progression-free survival among patients with 
brain metastases will be reported separately. 
Secondary end points included overall survival, 
progression-free survival (investigator assessment), 
objective response, and safety. Imaging (CT or 
MRI) was performed every 6 weeks for 36 weeks, 
then every 9 weeks thereafter, until disease pro-
gression leading to treatment discontinuation. 
Responses required confirmatory scans 4 to 6 
weeks later. Patients were contacted every 4 weeks 
to assess survival during long-term follow-up.
Safety was evaluated in all treated patients 
according to the Medical Dictionary for Regulatory 
Activities, version 22.1, and the severity of adverse 
events was coded according to the National Can-
cer Institute Common Terminology Criteria for 
Adverse Events, version 4.03. Premedication for 
infusion reactions was recommended, antiemet-
ics and supportive measures were allowed, and 
diarrhea was treated at its onset (details are pro-
vided in the Methods section in the Supplemen-
tary Appendix).
Statistical Analysis
Anticipated enrollment was 488 patients, includ-
ing patients with or without brain metastases at 
baseline, with a 15% cap for patients with brain 
metastases. The efficacy analyses involved the 
patients without brain metastases at baseline as 
well as the full trial population. Under the as-
sumption of a hazard ratio for disease progres-
sion or death (sacituzumab govitecan vs. chemo-
therapy) of 0.667, 315 events of progression or 
death would provide an estimated 95% power 
to detect a significant between-group difference 
in progression-free survival in the primary efficacy 
population; the expected progression-free survival 
with sacituzumab govitecan was 4.5 months, as 
compared with 3 months with chemotherapy of 
the physician’s choice. To control for type I error 
at a two-sided alpha level of 0.05, a hierarchical 
testing procedure (gatekeeping) was implemented 
for testing progression-free and overall survival. 
On the unanimous recommendation of the data 
and safety monitoring committee, the trial was 
halted in March 2020, and the process to con-
duct a final analysis was initiated owing to com-
pelling evidence of efficacy.
Progression-free survival was defined as the 
time from randomization until objective tumor 
progression or death or was censored at the last 
radiographic assessment for patients without pro-
gression or death. Progression-free survival, over-
all survival, and response duration were analyzed 
with the use of the Kaplan–Meier method, with 
medians and corresponding 95% confidence in-
tervals determined according to the Brookmeyer 
and Crowley method with log–log transforma-
tion. The 95% confidence intervals were not ad-
justed for multiplicity and cannot be used to 
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infer treatment effects. Treatment effect was 
compared with the use of a stratified log-rank 
test. Hazard ratios and their 95% confidence 
intervals were estimated with the use of a strat-
ified Cox proportional-hazards model. The per-
centage of patients with an objective response 
was compared between the treatment groups 
with the use of the stratified Cochran–Mantel–
Haenszel method. The same stratification fac-
tors that were used for the randomization were 
used in the stratified efficacy analyses.
R esult s
Patient Characteristics
A total of 529 patients with triple-negative breast 
cancer were enrolled between November 2017 
and September 2019 at 88 sites in seven coun-
tries and were randomly assigned in a 1:1 ratio 
to receive sacituzumab govitecan or single-agent 
chemotherapy. A total of 61 patients had brain 
metastases at baseline, and 468 patients had no 
evidence of brain metastases (primary trial popu-
lation for the analysis of efficacy); 235 patients 
were assigned to receive sacituzumab govitecan 
and 233 patients to receive single-agent chemo-
therapy prespecified by the investigator (54% 
eribulin, 20% vinorelbine, 13% capecitabine, and 
12% gemcitabine). A total of 32 patients who 
were assigned to receive chemotherapy received 
no trial drug (26 patients) or withdrew consent 
(6 patients) before treatment; these 32 patients 
are included in the efficacy analysis but not in 
the safety analyses.
Patients had a median age of 54 years (range, 
27 to 82); previous treatments included taxanes 
(100%), anthracyclines (82%), carboplatin (66%), 
inhibitors of programmed death 1 (PD-1) or pro-
grammed death ligand 1 (PD-L1) (27%), and 
poly(adenosine diphosphate–ribose) polymerase 
(PARP) inhibitors (7%) (Table 1). Patients had 
discontinued their previous treatment primarily 
because of progressive disease (78%); 3% had 
discontinued because of adverse events. Approxi-
mately 30% of the patients were not triple-nega-
tive at initial diagnosis, and this discordance 
between primary tumor staining and metastatic 
recurrence underscores the importance of ob-
taining biopsy samples at the time of recurrence. 
At the time of data cutoff (March 11, 2020), 15 of 
235 patients (6%) continued to receive sacituzu-
mab govitecan and 0 of 233 patients continued 
to receive chemotherapy (Fig. S2).
Efficacy in Patients without Brain Metastases
As of the March 11, 2020, data cutoff, the median 
follow-up time from patients’ randomization date 
was 17.7 months (range, 5.8 to 28.1). The median 
progression-free survival as determined by cen-
tral review (primary end point) was 5.6 months 
(95% confidence interval [CI], 4.3 to 6.3) with 
sacituzumab govitecan and 1.7 months (95% CI, 
1.5 to 2.6) with chemotherapy (hazard ratio for 
disease progression or death, 0.41; 95% CI, 0.32 
to 0.52; P<0.001) (Table 2 and Fig. 1A). Progres-
sion-free survival as determined by central review 
was consistent with investigator assessments 
(5.5 months with sacituzumab govitecan and 1.7 
months with chemotherapy; hazard ratio for dis-
ease progression or death, 0.35; 95% CI, 0.28 to 
0.44) (Fig. S3). The median overall survival was 
12.1 months (95% CI, 10.7 to 14.0) with sacituzu-
mab govitecan and 6.7 months (95% CI, 5.8 to 
7.7) with chemotherapy (hazard ratio for death, 
0.48; 95% CI, 0.38 to 0.59; P<0.001) (Table 2 and 
Fig. 1B).
The progression-free survival benefit of sacituzu-
mab govitecan over chemotherapy was consis-
tently observed across all predefined subgroups 
(Fig. 2), including patients 65 years of age or older 
(median, 7.1 vs. 2.4 months), those with more 
than three previous therapies (5.6 vs. 2.5 months), 
those with previous use of PD-1 or PD-L1 in-
hibitors (4.2 vs. 1.6 months), those with triple-
negative breast cancer at initial diagnosis (5.7 vs. 
1.6 months), those without triple-negative breast 
cancer at initial diagnosis (4.6 vs. 2.3 months), 
and those with liver metastases (4.2 vs. 1.5 
months). Subgroup analyses of median overall 
survival similarly favored sacituzumab govitecan 
over chemotherapy (Fig. S4).
The percentage of patients with an objective 
response was 35% with sacituzumab govitecan 
and 5% with chemotherapy (Table 2 and Fig. 1C). 
Clinical benefit was also noted in all subgroups 
evaluated (Fig. S5). The median duration of re-
sponse was 6.3 months (95% CI, 5.5 to 9.0) with 
sacituzumab govitecan and 3.6 months (95% CI, 
2.8 to could not be estimated) with chemother-
apy (hazard ratio, 0.39; 95% CI, 0.14 to 1.07) 
(Fig. S6). The median time to response was 1.5 
months (range, 0.7 to 10.6) with sacituzumab 
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govitecan and 1.5 months (range, 1.3 to 4.2) with 
chemotherapy.
Efficacy in the Full Population
Among all randomly assigned patients (with or 
without brain metastases), the median progres-
sion-free survival was 4.8 months (95% CI, 4.1 to 
5.8) with sacituzumab govitecan and 1.7 months 
(95% CI, 1.5 to 2.5) with chemotherapy (hazard 
ratio for disease progression or death, 0.43; 95% 
CI, 0.35 to 0.54) (Table 2 and Fig. 1D). The me-
dian overall survival was 11.8 months (95% CI, 
10.5 to 13.8) with sacituzumab govitecan and 
6.9 months (95% CI, 5.9 to 7.7) with chemo-
therapy (hazard ratio, 0.51; 95% CI, 0.41 to 0.62) 
(Fig. S7).
Safety
The safety population consisted of the 482 pa-
tients who received at least one treatment dose 
(258 in the sacituzumab govitecan group and 
224 in the chemotherapy group). The median 
relative dose intensity with sacituzumab govite-
can was 99.7%; patients received sacituzumab 
govitecan for a median of 4.4 months (maxi-
mum, 22.9 months). Overall, 99.6% of the pa-
tients in the sacituzumab govitecan group and 
99.1% of those in the chemotherapy group re-
ceived preinfusion or concomitant medication 
(see the Results section in the Supplementary 
Appendix).
The most common treatment-related adverse 
events of any grade were neutropenia (63% with 
sacituzumab govitecan and 43% with chemo-
therapy), diarrhea (59% and 12%), nausea (57% 
and 26%), alopecia (46% and 16%), fatigue (45% 
and 30%), and anemia (34% and 24%) (Table 3). 
The most frequent treatment-related adverse 
events of grade 3 or higher were neutropenia 
(51% with sacituzumab govitecan and 33% with 
chemotherapy), leukopenia (10% and 5%), diar-
rhea (10% and <1%), anemia (8% and 5%), and 
febrile neutropenia (6% and 2%). In the sacituzu-
mab govitecan group, treatment-related adverse 
events involving rash of any grade (in 22 patients 
[9%] overall; 1 patient with a grade 3 event) and 
ocular toxic effects (in 12 patients [5%]; no pa-
tients with an event of grade >1) occurred with 
low incidence, and no neuropathy of greater 
than grade 2 was observed. No grade 1 or 2 in-
terstitial lung disease was reported, and grade 3 
pneumonitis developed in 1 patient (see the Re-
sults section in the Supplementary Appendix). In 
the chemotherapy group, treatment-related adverse 
events involving rash of any grade (in 3 patients 
[1%] overall; 1 patient with a grade 3 event), 
ocular toxic effects (in 6 patients [3%]; no pa-
tients with an event of grade >2), and neuropa-
thy of greater than grade 2 (2 patients [1%]) 
occurred at low frequency, and no interstitial 
lung disease was reported.
Neutropenia was managed with dose reduc-
tion, dose delay, or both and with growth-factor 
support after day 1 of cycle 1. The incidence of 
grade 3 and 4 febrile neutropenia was 5% and 
1%, respectively, with sacituzumab govitecan and 
2% and less than 1%, respectively, with chemo-
therapy. Concomitant growth-factor support was 
given to 49% of the patients treated with sacituzu-
mab govitecan and 23% of those treated with 
chemotherapy. (For dose-modification recommen-
dations for severe neutropenia and nonneutro-
penic toxic effects, see Fig. S8.) Diarrhea (pre-
dominantly of grade 1) was a common adverse 
event; the incidence of grade 3 diarrhea was 10% 
with sacituzumab govitecan and less than 1% with 
chemotherapy, and no grade 4 events were noted 
in either group (Table 3).
Serious treatment-related adverse events were 
reported in 39 patients (15%) treated with sacituzu-
mab govitecan and 19 patients (8%) treated with 
chemotherapy. Dose reductions due to adverse 
events occurred with similar frequency in the 
two groups (22% of the patients who received 
sacituzumab govitecan and 26% of those who 
received chemotherapy). Adverse events leading 
to treatment discontinuation were infrequent, oc-
curring in 12 patients (5%) in each group. A total 
of 3 patients treated with sacituzumab govitecan 
and 3 treated with chemotherapy died owing to 
adverse events (in the sacituzumab govitecan 
group, owing to respiratory failure [2 patients] 
and postobstructive pneumonia [1 patient]; in 
the chemotherapy group, owing to neutropenic 
sepsis, sepsis, and general physical health deteri-
oration related to progressive disease [1 patient 
each]). None of the deaths in the sacituzumab 
govitecan group were deemed to be treatment-
related, whereas one death in the chemotherapy 
group was deemed to be treatment-related (neu-
tropenic sepsis; see the Results section in the 
Supplementary Appendix).
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Sex — no. (%)
Female 233 (99) 233 (100)
Male 2 (1) 0
Median age (range) — yr 54 (29–82) 53 (27–81)
Race or ethnic group — no. (%)‡
White 188 (80) 181 (78)
Black 28 (12) 28 (12)
Asian 9 (4) 9 (4)
Other or not specified 10 (4) 15 (6)
ECOG performance-status score at screening — no. (%)§
0 108 (46) 98 (42)
1 127 (54) 135 (58)
Germline BRCA1 or BRCA2 mutation status — no. (%)¶
Negative 133 (57) 125 (54)
Positive‖ 16 (7) 18 (8)
Triple-negative breast cancer at initial diagnosis — no. (%)
Yes 165 (70) 157 (67)
No** 70 (30) 76 (33)
Median time from diagnosis of metastatic disease to enrollment (range) 
— mo††
15.8 (0–202.9) 15.2 (0–140.1)
Major tumor locations — no. (%)‡‡
Lung 108 (46) 97 (42)
Liver 98 (42) 101 (43)
Axillary lymph nodes 57 (24) 73 (31)
Bone§§ 48 (20) 55 (24)
Median no. of previous anticancer regimens (range) ¶¶ 3 (1–16) 3 (1–12)
Previous chemotherapy regimens — no. (%)
2 or 3 166 (71) 164 (70)
>3 69 (29) 69 (30)
Previous chemotherapy drugs — no. (%)‖‖
Taxanes 235 (100) 233 (100)
Anthracyclines 191 (81) 193 (83)
Cyclophosphamide 192 (82) 192 (82)
Carboplatin 147 (63) 160 (69)
Capecitabine 147 (63) 159 (68)
Previous use of PARP inhibitors — no. (%) 17 (7) 18 (8)
Previous use of PD-1 or PD-L1 inhibitors — no. (%) 67 (29) 60 (26)
*  PARP denotes poly(adenosine diphosphate–ribose) polymerase, PD-1 programmed death 1, and PD-L1 programmed
death ligand 1.
†  The chemotherapy group included patients randomly assigned to receive eribulin (126 patients), vinorelbine (47), 
capecitabine (31), and gemcitabine (29).
‡  Race was reported by the patients.
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§  Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating that
the patient is fully active with no restrictions, 1 indicating that the patient is ambulatory and able to carry out work
of a light or sedentary nature but restricted in physically strenuous activity, and higher numbers indicating increasing
degrees of disability.
¶  Patients who did not undergo BRCA1 or BRCA2 germline testing or who had inconclusive results are not included.
‖  Among the patients with BRCA1 or BRCA2 mutations at baseline, 10 of 16 (62%) in the sacituzumab govitecan group 
and 11 of 18 (61%) in the chemotherapy group had previously received PARP inhibitors.
**  Patients whose initial diagnosis was hormone receptor–positive or human epidermal growth factor receptor 2–positive 
breast cancer had a median time from diagnosis of metastatic disease to enrollment of 22.5 months (range, 2.1 to 
202.9) in the sacituzumab govitecan group and 21.2 months (range, 1.1 to 140.1) in the chemotherapy group.
††  The time from diagnosis of metastatic disease is defined as number of days from the date of first diagnosis of metas-
tasis to the date of trial entry divided by 30.4375.
‡‡  Tumor locations were based on independent central review of target and nontarget lesions at baseline.
§§  Patients with bone-only disease were not permitted in the trial.
¶¶  Anticancer regimens refer to any previous regimens for metastatic or locally advanced disease or in the neoadjuvant
context that were used to treat an eligible patient with breast cancer. Previous therapy in the adjuvant context is exclud-
ed from this count.
‖‖  Shown are most common chemotherapy drugs used. Taxanes include paclitaxel, nab-paclitaxel, and docetaxel. 
Anthracyclines include doxorubicin, daunorubicin, epirubicin, and different formulations of these agents.
Table 1. (Continued.)
Table 2. Summary of Treatment Efficacy, as Determined by Independent Central Review.*











Median progression-free survival (95% CI) — mo 5.6 (4.3−6.3) 1.7 (1.5−2.6) 4.8 (4.1–5.8) 1.7 (1.5–2.5)
Hazard ratio for disease progression or death 
(95% CI)
0.41 (0.32−0.52)‡ 0.43 (0.35−0.54)
Median overall survival (95% CI) — mo 12.1 (10.7−14.0) 6.7 (5.8−7.7) 11.8 (10.5–13.8) 6.9 (5.9–7.7)
Hazard ratio for death (95% CI) 0.48 (0.38−0.59)‡ 0.51 (0.41–0.62)
Objective response — no. of patients (%)§ 82 (35) 11 (5) 83 (31) 11 (4)
Complete response 10 (4) 2 (1) 10 (4) 2 (1)
Partial response 72 (31) 9 (4) 73 (27) 9 (3)
Clinical benefit — no. of patients (%)¶ 105 (45) 20 (9) 108 (40) 21 (8)
Stable disease — no. of patients (%) 81 (34) 62 (27) 96 (36) 71 (27)
Stable disease for ≥6 mo 23 (10) 9 (4) 25 (9) 10 (4)
Progressive disease — no. of patients (%) 54 (23) 89 (38) 65 (24) 100 (38)
Response could not be evaluated — no. of patients 
(%)‖
18 (8) 71 (30) 23 (9) 80 (31)
Median time to response (95% CI) — mo 1.5 (0.7−10.6) 1.5 (1.3−4.2) 1.5 (0.7–10.6) 1.5 (1.3−4.2)
Median duration of response (95% CI) — mo 6.3 (5.5−9.0) 3.6 (2.8−NE) 6.3 (5.5–9.0) 3.6 (2.8–NE)
Hazard ratio (95% CI) 0.39 (0.14−1.07)
*  NE denotes could not be estimated.
†  The full population includes all randomly assigned patients (with and without brain metastases).
‡  P<0.001.
§  An objective response was defined as a complete response or partial response.
¶  Clinical benefit was defined as a complete response, a partial response, or stable disease with a duration of at least 6 months.
‖  Response could not be evaluated for a variety of reasons, including a lack of postbaseline images or unreadable images.
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Discussion
This phase 3, randomized clinical trial involving 
patients with metastatic triple-negative breast 
cancer showed a significant benefit of sacituzu-
mab govitecan, a Trop-2–directed antibody–drug 
conjugate, over chemotherapy with respect to 
progression-free survival (hazard ratio for dis-
ease progression or death, 0.41; P<0.001) and 
overall survival (hazard ratio for death, 0.48; 
P<0.001). The benefit with sacituzumab govitecan 
was seen in all clinical and prespecified sub-
groups, including patients who received previous 
treatment with PD-1 or PD-L1 inhibitors. The per-
centage of patients with an objective response 
was higher with sacituzumab govitecan than 
with chemotherapy (35% vs. 5%). A similar clini-
cal benefit in progression-free and overall sur-
vival was observed in the full trial population of 
patients with or without brain metastases.
Although cross-trial comparisons should be 
made with caution, the results with single-agent 
chemotherapy (control group) that were observed 
in this trial are broadly consistent with survival 
rates in previous studies.5-9 The KEYNOTE-119 
trial, which involved patients who were less 
Figure 1 (facing page). Efficacy Results in Patients without 
Brain Metastases at Baseline and in the Full Population.
Panels A and B show progression-free and overall surviv-
al, respectively, among patients without brain metasta-
ses. Progression-free survival was determined by blind-
ed independent central review according to Response 
Evaluation Criteria in Solid Tumors, version 1.1. Panel C 
shows a waterfall plot of the best percent change in the 
sum of the diameters of target lesions in patients with-
out brain metastases who had at least one response as-
sessment by central review (212 patients in the sacituzu-
mab govitecan group and 160 in the chemotherapy 
group). Asterisks at 0 denote patients who had no 
change from baseline in tumor size. Panel D shows 
progression-free survival among all randomly  assigned 
patients (with or without brain metastases).
Figure 2. Subgroup Analysis of Progression-free Survival.
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Any Grade Grade 3 Grade 4 Any Grade Grade 3 Grade 4
number of patients (percent)
Any adverse event 252 (98) 117 (45) 48 (19) 192 (86) 71 (32) 33 (15)
Hematologic event
Neutropenia† 163 (63) 88 (34) 44 (17) 96 (43) 45 (20) 29 (13)
Anemia‡ 89 (34) 20 (8) 0 54 (24) 11 (5) 0
Leukopenia§ 41 (16) 23 (9) 3 (1) 25 (11) 10 (4) 2 (1)
Thrombocytopenia¶ 14 (5) 2 (1) 2 (1) 25 (11) 3 (1) 0
Febrile neutropenia 15 (6) 12 (5) 3 (1) 5 (2) 4 (2) 1 (<1)
Gastrointestinal event
Diarrhea 153 (59) 27 (10) 0 27 (12) 1 (<1) 0
Nausea 147 (57) 6 (2) 1 (<1) 59 (26) 1 (<1) 0
Vomiting 75 (29) 2 (1) 1 (<1) 23 (10) 1 (<1) 0
Constipation 44 (17) 0 0 32 (14) 0 0
Abdominal pain 29 (11) 3 (1) 0 9 (4) 1 (<1) 0
General disorders and administration-
site conditions
Fatigue 115 (45) 8 (3) 0 68 (30) 12 (5) 0
Asthenia 31 (12) 2 (1) 0 23 (10) 3 (1) 0
Skin and subcutaneous disorders: 
alopecia‖
119 (46) 0 0 35 (16) 0 0
Metabolism and nutrition disorders: 
decreased appetite
51 (20) 4 (2) 0 32 (14) 1 (<1) 0
Nervous system disorders**†† 64 (25) 1 (<1) 0 53 (24) 5 (2) 0
Respiratory, thoracic, and mediastinal 
disorders††
41 (16)    5 (2)‡‡ 0 17 (8) 1 (<1) 0
Musculoskeletal and connective-tissue 
disorders††
32 (12) 0 0 28 (12) 3 (1) 0
Infections and infestations†† 30 (12) 6 (2) 1 (<1) 22 (10) 4 (2) 3 (1)
*  Shown are adverse events of any grade that occurred in at least 10% of the patients in either treatment group and adverse events of grade 3 or
higher that occurred in at least 5% of the patients in either treatment group. The safety population included all the patients who received
at least one dose of trial treatment, irrespective of status with respect to brain metastases at baseline.
†  The neutropenia category included neutropenia and decreased neutrophil count.
‡  The anemia category included anemia, decreased hemoglobin level, and decreased red-cell count.
§  The leukopenia category included leukopenia and decreased white-cell count.
¶  The thrombocytopenia category included thrombocytopenia and decreased platelet count.
‖  With respect to skin and subcutaneous disorders, there was one grade 3 rash in each of the sacituzumab govitecan and chemotherapy groups.
**  There were no grade 3 or 4 neuropathy events with sacituzumab govitecan. In the chemotherapy group, there were grade 3 events of periph-
eral neuropathy (in two patients) and peripheral sensory neuropathy (in two patients).
††  For this category, the overall incidence of adverse events of any grade was at least 10%, but the incidence of all individual adverse events 
of any grade was 5% or less.
‡‡  There was one case of grade 3 pneumonitis in the sacituzumab govitecan group (see the Supplementary Appendix); there were none in 
the chemotherapy group.
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heavily pretreated than those in the ASCENT 
trial, compared second- or third-line pembrolizu-
mab with standard chemotherapy; efficacy out-
comes were aligned with historical expectations 
of single-agent chemotherapy (median progres-
sion-free survival of 3.3 months and median 
overall survival of 10.8 months).9 A pooled analy-
sis of two phase 3 studies (EMBRACE and Study 
301) included 428 patients with triple-negative
breast cancer: 243 patients received eribulin, and
185 received control (treatment of the physician’s
choice in EMBRACE and capecitabine in Study
301). The pooled analysis showed a 2.8-month
median progression-free survival and 12.9-month 
median overall survival with eribulin and a
2.6-month progression-free survival and 8.2-month
overall survival with standard chemotherapy.27
Sacituzumab govitecan has toxic effects that 
may require management; however, our trial 
showed a low incidence of treatment discontinu-
ation due to adverse events (5%). Sacituzumab 
govitecan was administered over a long dura-
tion, up to 22.9 months (median, 4.4 months). 
The most clinically relevant grade 3 or 4 adverse 
events with sacituzumab govitecan were neutro-
penia and diarrhea, which were managed with 
established supportive care measures. The inci-
dence of treatment-related pneumonitis or inter-
stitial lung disease was low, with only one pa-
tient having reversible grade 3 pneumonitis in 
the context of multiple confounding factors.
Although sacituzumab govitecan is the only 
antibody–drug conjugate approved for metastatic 
triple-negative breast cancer in the United States, 
antibody–drug conjugates have been established 
as treatment options in HER2-positive breast can-
cer.28 Both ado-trastuzumab emtansine (T-DM1)29 
and fam-trastuzumab deruxtecan-nxki (DS-8201a)30 
are approved for patients with HER2-positive dis-
ease. Ado-trastuzumab emtansine combines 
trastuzumab with a microtubule inhibitor DM1 
through a thioether linker, with toxic effects 
(e.g., thrombocytopenia and hepatotoxic effects) 
associated with the cytotoxic component.29 
Fam-trastuzumab deruxtecan-nxki combines an 
anti-HER2 fam-trastuzumab with a topoisomer-
ase inhibitor, deruxtecan (an exatecan deriva-
tive), as its payload, with toxic effects (myelosup-
pression, diarrhea, and the rare but known toxic 
effect of potentially fatal interstitial lung dis-
ease) associated with the cytotoxic component.31
Potential limitations of the current trial in-
cluded the number of patients assigned to the 
chemotherapy group (32) who withdrew consent 
before the initiation of trial treatment or who 
decided not to start trial treatment. The com-
parison of sacituzumab govitecan with multiple 
standard-of-care chemotherapies also provided 
some challenges owing to the heterogeneity of 
safety risks associated with each chemotherapy 
agent, and the trial was not powered to exam-
ine differences between the individual agents. 
Tissue biopsies were optional rather than pro-
tocol-mandated immediately before trial entry.
Sacituzumab govitecan is a first-in-class, 
Trop-2–directed antibody–drug conjugate18; it 
showed a significant benefit with respect to 
progression-free and overall survival as compared 
with standard-of-care chemotherapy. Toxic effects, 
particularly myelosuppression and diarrhea, were 
more frequent with sacituzumab govitecan than 
with chemotherapy. Multiple studies of sacituzu-
mab govitecan involving patients with breast 
cancer are under way, including evaluation of 
the agent as neoadjuvant therapy in early triple-
negative breast cancer (NeoSTAR [Clinical-
Trials.gov number, NCT04230109]), as adjuvant 
therapy (GBG102-SASCIA [EudraCT number, 2019 
- 004100 - 35]), in the metastatic context in com-
bination with immunotherapy-based regimens
(Morpheus-TNBC [ClinicalTrials.gov number,
NCT03424005] and Saci-IO TNBC [NCT04468061])
or with a PARP inhibitor (NCT04039230) in ad-
vanced triple-negative breast cancer, and in hor-
mone receptor–positive and HER2-negative meta-
static breast cancer (TROPiCS-02 [NCT03901339]).
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